DavidMcCallMD

Pediatric Hematology & Oncology • Houston, TX

Pediatric Hematologic Oncology

Assistant Professor

Join to view full profile

Dr. McCall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McCall's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

Medical College of Georgia at Augusta UniversityClass of 2014

Certifications & Licensure

WA State Medical License 2023 - 2026
AL State Medical License 2016 - 2025
AZ State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2023 - 2025
TN State Medical License 2023 - 2025
TX State Medical License 2017 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology
Join now to see all

Clinical Trials

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma Start of enrollment: 2022 Oct 05
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Impact Of Muscle Vibration On Gait Control Start of enrollment: 2021 Oct 04
RECRUITING
NA
Roles: Principal Investigator, Contact
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia Start of enrollment: 2023 Jul 14
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias Start of enrollment: 2024 Dec 27
RECRUITING
PHASE1
Roles: Principal Investigator, Contact
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias Start of enrollment: 2025 Feb 18
RECRUITING
PHASE1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Treatment of a Pediatric Patient with Core Binding Factor Acute Myeloid Leukemia Post-Cytotoxic Therapy With Cytarabine, Daunorubicin, and Gemtuzumab Followed by Stem ...
Irtiza N Sheikh, Destiny Uwaezuoke, Olayinka Okeleji, Andres Quesada, Cynthia E Herzog
Pediatric Blood & Cancer. 2025-03-01
Calasparagase Pegol Induced Hemolytic Anemia.
Ariel Nash, Christine Nguyen Dinh, Jitesh Kawedia, David McCall, Stacy Weinman
Pediatric Blood & Cancer. 2025-03-01
MENIN MAINTENANCE THERAPY FOR ACUTE LEUKEMIA.
Olayinka Okeleji, David McCall, Amber Gibson, Miriam B Garcia, Cesar Nunez
Blood Advances. 2025-02-24

Press Mentions

ASH: Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory DisorderDecember 9th, 2024